Personalized Cytokine Management System

Publication ID: 24-11857550_0010_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Personalized Cytokine Management System,” Published Technical Disclosure No. 24-11857550_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857550_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,550.

Summary of the Inventive Concept

A next-generation system for detecting, preventing, and treating cytokine-related disorders, leveraging wearable devices, AI-driven profiling, and targeted micro-dosing to provide personalized care.

Background and Problem Solved

The original patent addressed the need for effective treatments of inflammatory disorders by inhibiting pro-inflammatory cytokine release. However, it relied on administering a fixed dose of the compound to subjects. The new inventive concept solves the problem of inadequate personalized treatment by integrating wearable devices, machine learning algorithms, and real-time micro-dosing to create a tailored approach for each individual.

Detailed Description of the Inventive Concept

The Personalized Cytokine Management System comprises four interconnected modules: 1) a wearable device that continuously monitors cytokine levels in the subject's blood; 2) a machine learning algorithm that analyzes the data to generate a unique cytokine profile for the subject; 3) a micro-dosing module that administers a customized amount of the compound: or a pharmaceutically acceptable salt thereof, based on the subject's profile; and 4) a user interface that provides real-time feedback and personalized recommendations for treatment. The system enables early detection of cytokine imbalances, prevents cytokine storms, and optimizes treatment outcomes.

Novelty and Inventive Step

The new inventive concept's novelty lies in its integration of wearable devices, AI-driven profiling, and real-time micro-dosing, which provides a paradigm shift in personalized cytokine management. The inventive step is the synergistic combination of these components, enabling a proactive, tailored approach to cytokine-related disorders.

Alternative Embodiments and Variations

Alternative embodiments may include the use of implantable devices, mobile apps, or cloud-based services to facilitate data analysis and treatment recommendations. Variations may involve the integration of additional biomarkers or the application of the system to other disease areas, such as cancer or autoimmune disorders.

Potential Commercial Applications and Market

The Personalized Cytokine Management System has significant commercial potential in the healthcare industry, particularly in the areas of precision medicine, wearable technology, and AI-driven diagnostics. The target market includes pharmaceutical companies, medical device manufacturers, and healthcare providers seeking to improve patient outcomes and reduce treatment costs.

Field of Art

Pharmaceutical biotechnology, specifically immunomodulatory drug delivery and cytokine management systems, requiring advanced knowledge of medical device design, machine learning, microfluidics, and pharmacological intervention strategies

Person of Ordinary Skill (PHOSITA) Profile

A professional with a PhD in biomedical engineering or pharmaceutical sciences, expertise in medical device design, proficiency in machine learning algorithms, understanding of cytokine biology, and experience with point-of-care diagnostic technologies

Obviousness Rationale

A PHOSITA would recognize that the personalized cytokine management system represents a predictable technological evolution of the source patent's core pharmaceutical intervention, applying known monitoring and data analysis techniques to enhance targeted drug delivery for inflammatory disorders. The integration of wearable sensing, AI-driven profiling, and micro-dosing represents a logical extension of existing medical technology frameworks for precision medicine. The technical variations demonstrate incremental improvements using standard engineering approaches to personalize pharmaceutical treatment strategies.

Obvious Combinations & Variations

Source Patent Element
Method for inhibiting pro-inflammatory cytokine release using specific pharmaceutical compounds
PTD Variation
Continuous cytokine monitoring via wearable device with real-time micro-dosing
Obviousness Reasoning
Predictable application of known monitoring technologies to enhance pharmaceutical intervention, representing a standard design optimization approach
Source Patent Element
Treatment of inflammatory disorders like sepsis and pneumonia
PTD Variation
Machine learning algorithm for generating personalized cytokine profiles
Obviousness Reasoning
Known technique of applying computational analysis to medical data for personalized treatment strategies, representing a standard approach in precision medicine
Source Patent Element
Pharmaceutical compound for managing inflammatory responses
PTD Variation
Microfluidic point-of-care device for detecting cytokine imbalances
Obviousness Reasoning
Predictable technological progression using established microfluidic sensing technologies to enhance diagnostic capabilities
Source Patent Element
Treatment methods targeting specific bacterial infection-induced inflammatory responses
PTD Variation
Gut-brain axis modulation approach using the pharmaceutical compound
Obviousness Reasoning
Logical extension of existing pharmaceutical intervention strategies, exploring additional therapeutic mechanisms using known scientific understanding
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857550 and the disclosed technological variations, a person having ordinary skill in the art would find the claimed personalized cytokine management system obvious, as the technical elements represent predictable combinations of known medical monitoring, computational, and pharmaceutical technologies that would be apparent to a skilled practitioner seeking to optimize inflammatory disorder treatment strategies.

Original Patent Information

Patent NumberUS 11,857,550
TitleBenzathine analogs
Assignee(s)UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, United States Government As Represented By The Department Of Veterans Affairs